Rodman & Renshaw Reiterates Buy on Emergent BioSolutions, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has reiterated its Buy rating on Emergent BioSolutions, maintaining a price target of $16.
September 13, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has reiterated its Buy rating on Emergent BioSolutions, maintaining a price target of $16. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $16 price target by Rodman & Renshaw indicates a positive outlook on Emergent BioSolutions' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100